Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
4,546
result(s) for
"Anderson, Daniel"
Sort by:
The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of the viral sequence highlights the transformative potential of this nucleic acid technology. Most clinical applications of mRNA to date have focused on vaccines for infectious disease and cancer for which low doses, low protein expression and local delivery can be effective because of the inherent immunostimulatory properties of some mRNA species and formulations. In addition, work on mRNA-encoded protein or cellular immunotherapies has also begun, for which minimal immune stimulation, high protein expression in target cells and tissues, and the need for repeated administration have led to additional manufacturing and formulation challenges for clinical translation. Building on this momentum, the past year has seen clinical progress with second-generation coronavirus disease 2019 (COVID-19) vaccines, Omicron-specific boosters and vaccines against seasonal influenza, Epstein–Barr virus, human immunodeficiency virus (HIV) and cancer. Here we review the clinical progress of mRNA therapy as well as provide an overview and future outlook of the transformative technology behind these mRNA-based drugs.
Anderson and colleagues discuss the progress and challenges of using mRNA for vaccines and immunotherapy.
Journal Article
Engineering circular RNA for potent and stable translation in eukaryotic cells
Messenger RNA (mRNA) has broad potential for application in biological systems. However, one fundamental limitation to its use is its relatively short half-life in biological systems. Here we develop exogenous circular RNA (circRNA) to extend the duration of protein expression from full-length RNA messages. First, we engineer a self-splicing intron to efficiently circularize a wide range of RNAs up to 5 kb in length in vitro by rationally designing ubiquitous accessory sequences that aid in splicing. We maximize translation of functional protein from these circRNAs in eukaryotic cells, and we find that engineered circRNA purified by high performance liquid chromatography displays exceptional protein production qualities in terms of both quantity of protein produced and stability of production. This study pioneers the use of exogenous circRNA for robust and stable protein expression in eukaryotic cells and demonstrates that circRNA is a promising alternative to linear mRNA.
Circular RNAs have recently been shown to have protein-coding potential. Here the authors design a self-splicing RNA that, when circularized, provides for stable high-yield protein production.
Journal Article
BTEC National information technology
This is a complete teaching and learning package for the 2011 specifications helping both students and tutors to get the best results.
Delivery technologies for genome editing
Key Points
Genome-editing systems have remarkable potential to treat genetic diseases. However, one of the major challenges facing their implementation is the safe and efficient intracellular delivery of genome-editing biomacromolecules, including nucleases and nucleic acids.
Nanoparticles encapsulating genome-editing biomacromolecules must be endocytosed by the cell of interest and reach the nucleus or cytoplasm to function; additional extracellular barriers are present for
in vivo
delivery.
Physical methods for
in vitro
and
ex vivo
delivery of genome-editing tools include electroporation, membrane deformation and microinjection.
Viral vectors are widely used to deliver DNA for genome editing and are typically integrase-defective lentiviral vectors (IDLVs), adenoviruses and adeno-associated viruses (AAVs); AAVs seem to be the most popular vector for
in vivo
applications.
Non-viral nanoparticles, most often made from synthetic and cationic lipid or polymer delivery materials, can be used to deliver genome-editing tools
in vitro
,
ex vivo
and
in vivo
, sometimes in combination with viral vectors.
At the time of writing, the genome-editing industry is in its infancy and includes ongoing and completed phase I and phase II clinical trials.
In addition to selecting an effective delivery material, scientists must consider safety (that is, off-target effects, immunogenicity and mutagenesis), the required amount of genomic modification for therapeutic benefit, and the duration of effects.
Genome editing has emerged as an attractive approach to therapeutically manipulate gene expression. Here, Anderson and colleagues provide an overview of genome-editing platforms, focusing on the methods and challenges of intracellular biomacromolecule delivery. Preclinical and clinical trials involving genome-editing technologies are also discussed.
With the recent development of CRISPR technology, it is becoming increasingly easy to engineer the genome. Genome-editing systems based on CRISPR, as well as transcription activator-like effector nucleases (TALENs) and zinc-finger nucleases (ZFNs), are becoming valuable tools for biomedical research, drug discovery and development, and even gene therapy. However, for each of these systems to effectively enter cells of interest and perform their function, efficient and safe delivery technologies are needed. This Review discusses the principles of biomacromolecule delivery and gene editing, examines recent advances and challenges in non-viral and viral delivery methods, and highlights the status of related clinical trials.
Journal Article
The last age of magic
\"Led by Wonder Woman this team of Zatanna, Swamp Thing, Man-Bat and Detective Chimp must bring the fight against all supernatural foes too big for the World's Greatest Super Heroes! Earth's magic once belonged to them. Now they want the magic back. But who exactly are they? It's up to the new Justice League Dark to find out and stop this nightmarish new threat at all costs! After the events of NO JUSTICE, Wonder Woman guides the misfit magic mix against enemies too fantastic even for the Justice League. Plus, what awful things are coming through the Tree of Wonder? Dark days ahead.\"-- Provided by publisher.
Book
Bio-Inspired Polymer Composite Actuator and Generator Driven by Water Gradients
Here we describe the development of a water-responsive polymer film. Combining both a rigid matrix (polypyrrole) and a dynamic network (polyol-borate), strong and flexible polymer films were developed that can exchange water with the environment to induce film expansion and contraction, resulting in rapid and continuous locomotion. The film actuator can generate contractile stress up to 27 megapascals, lift objects 380 times heavier than itself, and transport cargo 10 times heavier than itself. We have assembled a generator by associating this actuator with a piezoelectric element. Driven by water gradients, this generator outputs alternating electricity at ∼0.3 hertz, with a peak voltage of ∼1.0 volt. The electrical energy is stored in capacitors that could power micro- and nanoelectronic devices.
Journal Article
Justice League Rebirth deluxe edition
\"Exploding from the pages of the blockbuster DC Universe Rebirth event, this deluxe edition collects the first eleven issues of the acclaimed series and the Rebirth special that started it, all together in one hardcover volume for the first time! Superman. Batman. Wonder Woman. The Flash. Cyborg. Green Lantern. They're more than just a team of superheroes. They're the Justice League...and they're about to enter a whole new era! The Superman these incredible heroes once knew is dead, leaving an older, wiser Man of Steel from a vanished universe to take up the fight against evil. Hal Jordan, the greatest of the Green Lanterns, has taken to the stars, entrusting his place in the League to his powerful but untested young proteges, Jessica Cruz and Simon Baz. Now the Justice League must get used to these new faces and learn to work as a team once more. But they'd better do it fast. They're about to confront the biggest threats they've ever faced, from godlike machines capable of converting all life on Earth into a weapon, to a humble hacker who's ready to hit them where it hurts most.\"-- Provided by publisher.
Book
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
ABSTRACTRheumatoid arthritis is a systemic autoimmune disease characterized by excess morbidity and mortality from cardiovascular disease. Mechanisms linking rheumatoid arthritis and cardiovascular disease include shared inflammatory mediators, post-translational modifications of peptides/proteins and subsequent immune responses, alterations in the composition and function of lipoproteins, increased oxidative stress, and endothelial dysfunction. Despite a growing understanding of these mechanisms and their complex interplay with conventional cardiovascular risk factors, optimal approaches of risk stratification, prevention, and treatment in the context of rheumatoid arthritis remain unknown. A multifaceted approach to reduce the burden posed by cardiovascular disease requires optimal management of traditional risk factors in addition to those intrinsic to rheumatoid arthritis such as increased disease activity. Treatments for rheumatoid arthritis seem to exert differential effects on cardiovascular risk as well as the mechanisms linking these conditions. More research is needed to establish whether preferential rheumatoid arthritis therapies exist in terms of prevention of cardiovascular disease. Ultimately, understanding the unique mechanisms for cardiovascular disease in rheumatoid arthritis will aid in risk stratification and the identification of novel targets for meaningful reduction of cardiovascular risk in this patient population.
Journal Article